ESMO 2019: KATE2 Suggests Benefit of Atezolizumab in PD-L1-Positive, HER2-Positive Breast Cancer
Study authors recommend further study of HER2-targeted agents plus atezolizumab in this patient population
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.